VTGN Vistagen Therapeutics, Inc.

Nasdaq Pharmaceutical Preparations NV CIK: 0001411685
AI RATING
STRONG_SELL
78% Confidence

Investment Thesis

Vistagen is a pre-commercial biotech company facing critical cash runway pressure with only ~5.5 months of cash remaining at current $66.4M annual burn rate, offsetting improvements in loss trajectory. While revenue grew 161% YoY and net losses declined 35.5% YoY, absolute losses of $72.1M on just $1.3M in revenue indicate the company remains years away from sustainable profitability without major clinical or financing catalysts.

Strengths

  • + Net losses improved 35.5% YoY, indicating operational leverage or cost controls gaining traction
  • + Revenue growth of 161% YoY demonstrates emerging commercial traction despite tiny absolute base
  • + Zero long-term debt with healthy balance sheet structure ($35.5M equity vs $13.0M liabilities)

Risks

  • ! Critical cash runway of only ~5.5 months at current $66.4M annual burn rate necessitates near-term capital raise
  • ! Massive operating losses (-$72.1M) on minimal revenue ($1.3M) indicates massive development stage risk
  • ! Severe profitability gap with negative operating margin of -5683% and negative FCF margin of -5235%

Key Metrics to Watch

Financial Metrics

Revenue
1.3M
Net Income
-69.7M
EPS (Diluted)
$-1.83
Free Cash Flow
-66.4M
Total Assets
48.6M
Cash
30.8M

Profitability Ratios

Gross Margin N/A
Operating Margin -5,683.7%
Net Margin -5,491.3%
ROE -196.2%
ROA -143.5%
FCF Margin -5,235.3%

Balance Sheet & Liquidity

Current Ratio
3.67x
Quick Ratio
3.67x
Debt/Equity
0.00x
Debt/Assets
26.9%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-06-18T07:22:25.883131 | Data as of: 2026-03-31 | Powered by Claude AI